Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 272,242
  • Shares Outstanding, K 126,624
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,830 K
  • 60-Month Beta 2.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.05
Trade ATOS with:

Options Overview Details

View History
  • Implied Volatility 102.20%
  • Historical Volatility 48.32%
  • IV Percentile 23%
  • IV Rank 7.93%
  • IV High 582.41% on 12/21/20
  • IV Low 60.83% on 10/28/21
  • Put/Call Vol Ratio 0.07
  • Today's Volume 1,970
  • Volume Avg (30-Day) 4,020
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 97,738
  • Open Int (30-Day) 116,849

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.11 +7.58%
on 11/30/21
2.91 -21.94%
on 11/04/21
-0.30 (-11.67%)
since 10/29/21
3-Month
2.11 +7.58%
on 11/30/21
4.31 -47.33%
on 09/02/21
-1.26 (-35.69%)
since 08/30/21
52-Week
0.81 +180.25%
on 12/17/20
9.80 -76.84%
on 06/25/21
+0.53 (+30.46%)
since 11/27/20

Most Recent Stories

More News
Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team”

Atossa’s CEO & Founder, Dr. Steven Quay, M.D., Ph.D. ...

ATOS : 2.27 (+5.58%)
Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop...

ATOS : 2.27 (+5.58%)
Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month

Global Pandemic Caused a Significant Drop In Mammograms as Clinics Remained Closed...

ATOS : 2.27 (+5.58%)
Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE

ATOS : 2.27 (+5.58%)
Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor

ATOS : 2.27 (+5.58%)
Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden

SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant...

ATOS : 2.27 (+5.58%)
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting

SEATTLE, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious...

ATOS : 2.27 (+5.58%)
Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021

SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant...

ATOS : 2.27 (+5.58%)
Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia

Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease

ATOS : 2.27 (+5.58%)
Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes

SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant...

ATOS : 2.27 (+5.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

3rd Resistance Point 2.45
2nd Resistance Point 2.39
1st Resistance Point 2.27
Last Price 2.27
1st Support Level 2.09
2nd Support Level 2.03
3rd Support Level 1.91

See More

52-Week High 9.80
Fibonacci 61.8% 6.37
Fibonacci 50% 5.31
Fibonacci 38.2% 4.24
Last Price 2.27
52-Week Low 0.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar